AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03114098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene abnormalities
Description: A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
Study NCT02533661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered intervention program
Description: This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
Study NCT02643381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
Study NCT02643381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
Study NCT02643381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency Endotracheal Intubation
Description: Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
Study NCT02643381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
Study NCT03205332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concreteness Training
Study NCT03192111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor
Study NCT00607919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
Study NCT00607919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily, for 16 weeks
Study NCT01989871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusted individual feeding
Description: Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
Study NCT02583516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib and cobimetinib
Description: Comparison between different treatment regimens
Study NCT04128618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyMedica e-vive NMES
Description: Neuromuscular Electrical Stimulation (NMES) therapy
Study NCT04128618 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CyMedica e-vive NMES
Description: Neuromuscular Electrical Stimulation (NMES) therapy
Study NCT03536923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leva Incontinence System For Pelvic Floor Muscle strengthening
Description: The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
Study NCT04088565 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Paired-Associative Stimulation (PAS)
Description: Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
Study NCT04088565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paired-Associative Stimulation (PAS)
Description: Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
Study NCT04088565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
Study NCT04088565 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sub-threshold stimulation that does not activate neural structures.
Study NCT02539914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality based upper-limb motor and cognitive task
Study NCT02539914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard upper-limb motor and cognitive rehabilitation tasks
Study NCT02795611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered occupational therapy
Description: Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
Study NCT02795611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regular occupational therapy
Description: regular occupational therapy
Study NCT01911650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
Study NCT01911650 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound Imaging
Description: A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
Study NCT01911650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: This questionnaire is a self-report of pain and function associated with the Achilles tendon.
Study NCT01911650 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: This questionnaire is a self-report of pain and function associated with the Achilles tendon.
Study NCT03671421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction - graft choice
Description: Use of 3 different ipsilateral autograft options
Study NCT02701959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Nitrate Lettuce
Description: The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).
Study NCT02701959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Nitrate Lettuce
Description: The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
Study NCT00255918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
Study NCT02795611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intervention done outside our hospital
Description: intervention done outside our hospital
Study NCT01527110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) zanamivir
Description: Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
Study NCT00509652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm 1: Erythrocyte apheresis
Description: Erythrocyte apheresis
Study NCT00255918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
Study NCT00509652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Whole blood phlebotomy
Description: Traditional whole blood phlebotomy
Study NCT03940014 — intervention group
Intervention type: OTHER
Intervention: Data collection from standard follow up
Description: Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months.
Study NCT02401113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UA group
Description: Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
Study NCT01785927 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ABCD
Description: Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
Study NCT02401113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UA group
Description: Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
Study NCT03999385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion (MSC)
Description: The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
Study NCT03999385 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful Self-Compassion (MSC)
Description: The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
Study NCT00805012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel+CDDP
Description: docetaxel+CDDP
Study NCT00805012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel+S-1
Description: docetaxel+S-1
Study NCT01570309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: Oral capsule, 50,000 units, once a week, 12 weeks
Study NCT00255918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dosed to match active medication
Study NCT01570309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Oral capsule, once a week, 12 weeks
Study NCT01425645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FDD program
Description: FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
Study NCT00615212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK376501
Description: GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
Study NCT00615212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
Study NCT00615212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
Study NCT00615212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
Study NCT00615212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
Study NCT00615212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
Study NCT00615212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
Study NCT04213183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatobiliary Disorders
Description: The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
Study NCT00255918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosed to match active medication
Study NCT00255918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
Study NCT00255918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
Study NCT02855021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Explorations
Description: Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment.
Study NCT03353363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
Study NCT03353363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
Study NCT03353363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
Study NCT02415244 — intervention group
Intervention type: PROCEDURE
Intervention: TEE
Description: Spinal cord segments will be imaged using the TEE
Study NCT01720875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat Velcade Dexamethasone
Study NCT03773900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kiotransine (chitin-glucan from aspergillus niger)
Description: The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
Study NCT03773900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
Study NCT02079909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA-H
Description: 224 mg or 448 mg T-817 MA once daily
Study NCT02079909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA-L
Description: 224 mg T-817 MA once daily
Study NCT02079909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02329977 — intervention group
Intervention type: OTHER
Intervention: standard barium meal examination
Description: All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
Study NCT02193009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SipSmarter
Description: 6-month behavioral trial
Study NCT02193009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MoveMore
Description: 6 month behavioral trial
Study NCT04930835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported dentures
Description: Placement of dental implants with different loading protocols for supporting full arch dentures.
Study NCT04930835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant supported dentures
Description: Placement of dental implants with different loading protocols for supporting full arch dentures.
Study NCT04009018 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Perioperative Satisfaction Scale in Regional Anesthesia
Description: This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
Study NCT03955783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth
Study NCT03955783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given by mouth
Study NCT02709512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 plus Pem Platinum
Description: Investigational Drug in combination approved standard of care treatment for this indication
Study NCT02709512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Pem Platinum
Description: Placebo in combination approved standard of care treatment for this indication
Study NCT01144624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773
Description: A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
Study NCT01144624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of a saline solution
Study NCT01876303 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01876303 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02678403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
Study NCT02678403 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
Study NCT00632775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids
Description: Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg.
Study NCT00632775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids
Description: Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg.
Study NCT00456755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shi-Bi-Lin
Description: 4 weeks of treatment, dose of 1 g (two capsules), twice daily
Study NCT00456755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
Study NCT01999244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring skills
Study NCT01999244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology
Study NCT01999244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventionist Contact
Study NCT04368013 — intervention group
Intervention type: PROCEDURE
Intervention: Extended sampling and procedures
Description: The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.